For decades, kinase inhibitors have been a mainstay of cancer therapy, designed to switch off enzymes that fuel uncontrolled cell growth. But new research shows that these drugs often go further: they can also cause the very proteins they target to be dismantled by the cell, making them yet another tool for the emerging field of Targeted Protein Degradation (TPD). In a new study published in Nature, scientists at CeMM and AITHYRA in Vienna, and the IRB in Barcelona, with partners across Europe, the US and China, have now mapped this effect systematically, uncovering a widespread but overlooked phenomenon in pharmacology.

An image-only artificial intelligence (AI) model for predicting the five-year risk of breast cancer provided stronger and more precise risk stratification than breast density assessment, according to a new study being presented next week at the annual meeting of the Radiological Society of North America (RSNA).

Lung cancer is the leading cause of cancer-related mortality worldwide. Elucidating the molecular programs that enable tumor cells to evade regulated cell death and anti-tumor immune responses is essential for developing effective therapeutic strategies. In this study, Wang and colleagues employ a series of genetically engineered non-small cell lung cancer mouse models, high-throughput lipidomics assays, and functional perturbation experiments to uncover how tumor cells adapt metabolically to escape ferroptosis and reprogram the tumor microenvironment for CD8⁺ T cell dysfunction.

Researchers at The University of Texas MD Anderson Cancer Center have found that renal medullary carcinoma (RMC) cells use an adaptive mechanism called “myeloid mimicry” to hide from the immune system and promote disease hyper progression after immunotherapy, highlighting specific targets that overcome treatment resistance in preclinical models.

Zanidatamab, a bispecific HER2-targeted antibody, delivered clinically meaningful and durable responses for patients with HER2-positive biliary tract cancer (BTC), according to final results from the HERIZON-BTC-01 clinical trial led by researchers at The University of Texas MD Anderson Cancer Center.

Researchers at the University of Gothenburg have discovered that milk from grey seals in the Atlantic Ocean may be more potent than breast milk. An analysis of seal milk found approximately 33 per cent more sugar molecules than in breast milk. Many of these sugars are unique and may pave the way for even better infant formula for babies.